Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 4 December 2025

 
 
 
   

A defining moment for European life sciences
 
Read more here.

Europe’s next chapter will be written by the choices we make today. And policy will be the driving force behind whether we succeed in correctly supporting our life sciences sector.

After more than three decades in the pharmaceutical industry, I know one thing: science transforms lives, but policy determines whether innovation thrives or stalls. That reality shapes outcomes for patients and for Europe’s competitiveness. Today, Europeans stand at a defining moment. The choices we make now will determine whether Europe remains a global leader in life sciences or we watch that leadership slip away.

 

Read more


 
 
 
   

News
 
Thumbnail

EFPIA response to the Council General Approach on the Critical Medicines Act
02 December 2025

EFPIA welcomes today’s adoption of the Council’s General Approach on the Critical Medicines Act (CMA). Read more
 
 
 
   

Blogs
 

Harmonizing health: Impact of international regulatory organisations on pharmaceutical regulatory...
04 December 2025

Global alignment is essential for timely access to innovation. This piece explores how ICH and other international organisations... Read more

Slovenia can become a European leader in Cancer Care: Insights from Dr. Thomas Hofmarcher (Guest...
02 December 2025

At the 2025 Tribuna of Hope, one of Slovenia’s most prominent annual gatherings of patient associations, oncology experts,... Read more
 
 
 
   

Europe has a choice to make

Clinical trials matter. They give patients the earliest access to new medicines, up to 5-10 years before launch and deliver €1-1.5bn to health systems every year. Yet in just five years, Europe has lost 60,000 clinical trial places. Europe is at a crossroads: bring clinical trials back or let the gap grow. 

Learn more here.
 
 
 
 
   

Events
 

Impact on TB: Partnerships joining forces to combat TB
09 December 2025 (Online)

How the partnerships embodied by IMI2 and EDCTP-2 led to the development of a novel modality for treating TB. Read more

Regulatory impact: what it is and how to achieve it with your IHI project
10 December 2025 (Online)

Join the IHI event on 10 December and seize the opportunity to hear from the EMA experts about the best ways for IHI... Read more
 
 
 
   

The Vaccines Europe pipeline review 2025 is now published

With 91 vaccines and monoclonal antibodies currently in development by our member companies, the report highlights the pivotal role innovation in immunisation plays in addressing emerging and persistent health threats.

It is vital that Europe prepares for this innovation. With the right policies in place, Europe can continue to lead in addressing its population’s evolving health needs and contribute to global health resilience.

We must prepare for tomorrow, today. Explore the pipeline here.
 
 
 
 
   

What we are reading

 
Belgium joins FAST-EU pilot accelerating multinational clinical trials
On 02 December 2025 (Euractiv)

Belgium is reducing mononational clinical trial approval timelines by 27 days per application.

Read more
BRIDGE project launches to advance regulatory sandboxes for healthcare innovation
On 02 December 2025 (Bridge)

The EU-funded BRIDGE project (Breakthrough Regulatory Innovation and Development throuGh sandbox Environments) officially... Read more
Trials@Home: Comprehensive recommendations for Decentralised Clinical Trials
On 01 December 2025 (Trials@Home )

Based on six years of multistakeholder scientific research on opportunities and challenges of decentralised clinical... Read more
Chinese pharma is on the cusp of going global
On 23 November 2025 (POLITICO)

After America, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu
EFPIA 2025 All rights reserved Disclaimer